Three-year clinical outcomes of a sirolimus-eluting bioresorbable scaffold (XINSORB) and a metallic stent to treat coronary artery stenosis.

BACKGROUND: Recent studies have shown increased risks of late target lesion failure (TLF) and thrombosis using a bioresorbable scaffold (BRS). However, the results of the ABSORB China study offered a different means of understanding the long-term performance of BRSs. We tested the 3-year clinical outcome of the XINSORB BRS in a multicenter, randomized controlled clinical trial (ChiCTR1800014966).
METHODS: Eligible patients with one or two de novo coronary lesions were randomly assigned 1:1 to be treated with XINSORB scaffolds and metallic sirolimus-eluting stents (SESs). The clinical endpoints include TLF [cardiac death, target vessel-related myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR)], its components, and devised thrombosis.
RESULTS: Three hundred ninety-five patients were enrolled and randomized to the XINSORB (N=200) and SES (N=195) arms. The clinical 3-year follow-up included 95.5% of the XINSORB-treated patients and 92.8% of the SES-treated patients. Dual antiplatelet therapy was at 59.0% of the XINSORB-treated and 52.8% of the SES-treated patients (P=0.34). There were no significant differences in the clinical outcomes between the XINSORB and SES arms, including in TLF (4.0% vs. 6.2%, P=0.29), cardiac death (1.0% vs. 0%, P=NA), TV-MI (1.0% vs. 0%, P=NA), and ID-TLR (3.5% vs. 6.2%, P=0.19). The rate of confirmed/probable device thrombosis in the XINSORB-treated patients was only 1.0% (2/200).
CONCLUSIONS: In this XINSORB randomized clinical trial, the XINSORB scaffolds and SESs showed similar efficacy and safety up to the 3-year follow-up. The rates of TLF and device thrombosis were low and comparable between the two arms. 2020 Annals of Translational Medicine. All rights reserved.

Introduction

Bioresorbable scaffolds (BRSs) (mainly referred to as BVS, Abbott Vascular, Santa Clara, CA, USA) showed favorable outcomes at a 1-year follow-up cobalt-chromium everolimus-eluting stent (XIENCE, Abbott Vascular, Santa Clara, CA, USA) (1). However, there were concerns that scaffold thrombosis and target lesion failure (TLF) after treatment with BVS increased beyond the 2-year follow-up (2-4). Yet to the results of ABSORB studies performed outside of China, the results from the ABSORB China study showed excellent clinical outcomes of treatment with BVS observed at three years. The rates of TLF (5.5% for BVS and 4.7% for XIENCE) and device thrombosis (0.9% for BVS and 0.0% for XIENCE) were low and comparable between the treatment arms (5,6). The XINSORB BRS (Shandong, Huaan, China) was a new device compared with BVS, and we have previously reported the first performance of the device (7,8). The long-term results of the XINSORB BRS in a first-in-human study were promising and showed acceptable efficacy with relatively low rate of scaffold thrombosis (9). The randomized control clinical trial of the XINSORB scaffold started in October 2014. The primary endpoint of one-year in-segment late luminal loss (LLL) of XINSORB was noninferior to the traditional metallic TIVOLI® sirolimus-eluting stent (SES) (0.19±0.32 vs. 0.31±0.41 mm, Pnoninferior=0.003). The rate of TLF was favorable for the XINSORB scaffold (2.5% for XINSORB and 5.1% for SES, P=0.17) (10). As a result, the XINSORB BRS was approved by China Food and Drug Administration in March 2020. Here, we report our analysis of the clinical results of the randomization part of the XINSORB clinical trial for up to three years. We present the following article in accordance with the CONSORT reporting checklist (available at http://dx.doi.org/10.21037/atm-20-6739).

Methods

Study devices

The XINSORB scaffold is composed of poly-L-lactic acid (PLLA). The design of the scaffold is like the ABSORB scaffold. Poly-D-L-lactic acid (PDLLA) mixed with PLLA carrying sirolimus is coated on the struts. The dosage of sirolimus ranges from 8–16 µg/mm, depending on the length of the scaffold. The thickness of the strut is 160 µm.

The commercially available TIVOLI® stent (Essen Technology, Beijing, China) is a cobalt-chromium SES with a biodegradable polymer. The efficacy and safety of this metallic stent have been confirmed in clinical trials (11,12).

Protocol, patient population, intervention, and follow-up

We previously reported the study design of the XINSORB randomized clinical trial (10). The study was registered at the official website of the China Clinical Trial Registry (ChiCTR1800014966). The study included a randomization part and a registry part. Briefly, the randomization part of the study was a prospective, randomized, multicenter trial. The study complied with the Good Clinical Practice guidelines of the China Food and Drug Administration. All procedures performed in this study involving human participants were in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by Zhongshan Hospital (No. 2014-44). Written informed consent was obtained before patient enrollment. Eligible patients were randomized at a 1:1 ratio to receive a XINSORB scaffold or SES. A maximum of 2 de novo lesions in different native coronary arteries is included. The lesions were visually assessed to be less than 24 mm, and the reference vessel diameter was from 2.75–3.5 mm. The percentage of stenosis was from 50% to 100%, with thrombolysis in myocardial infarction (TIMI) flow grade greater than 1. The procedures were performed through the standard process. Both predilation of the target lesion and the post-dilation of the implanted scaffold are mandatory. Post dilation for metallic stents was recommended. If the post-dilation of a XINSORB scaffold was needed, the diameter of the non-compliant balloon was required to be shorter and a maximum of 0.25 mm larger than the device. All patients received regular clinical follow-up examinations at 30, 90, 180, and 270 days and 1, 2, 3, 4, and 5 years. Patients were angiographically examined at one year after the index procedure. Follow-up examinations up to three years were completed at the time of the present report. Clopidogrel was prescribed for at least 12 months, and aspirin was continued for the duration of the study. On-site monitoring of 100% of the trial data was performed.

The study is registered at official website of China Clinical Trial Registry (ChiCTR1800014966).

Endpoints and definitions

The primary endpoint for randomization was angiographic in-segment LLL, defined as the difference in the minimal luminal diameter from post-procedure to 12 months, to show the noninferiority of the XINSORB scaffold to the SES. The secondary endpoints included the device-oriented composite endpoint (DoCE) of TLF [cardiac death, target vessel-related myocardial infarction (TV-MI), or ischemia-driven target lesion revascularization (ID-TLR)], the patient-oriented composite endpoint (PoCE; all-cause death, all MI, or all revascularization), target vessel failure (TVF) [cardiac death, MI, or ischemia-driven target vessel revascularization (ID-TVR)], major adverse cardiac events (MACE) (cardiac death, MI, or ID-TLR), the individual component endpoints of these endpoints, and device thrombosis. Device thrombosis was defined as acute (<24 hours), subacute (1 to 30 days), late (30 days to 1 year), and very late (beyond one year), and the level of evidence (definite or probable) was on the Academic Research Consortium definition (13). An independent clinical event committee watched all clinical events.

Statistical analysis

All analyses were performed according to the intention-to-treat (ITT) principle. Continuous variables are presented as the mean ± SD, and categorical variables are presented as counts and percentages. Normally distributed student’s t-test compared continuous variables. Categorical variables are compared using the chi-squared test or Fisher’s exact test. The cumulative event rates of the 3-year clinical outcomes were calculated from Kaplan-Meier estimates and were compared with the log-ranking test. Cox proportional-hazard regression was used to find the hazard ratios (HRs) and corresponding 95% confidential intervals (CIs).

All statistical analyses were two-sided and performed with a significance level of 0.05 using SAS software, version 9.4 (SAS Institute, Cary, North Carolina).

Results

Patients and baseline characteristics

Between October 2014 and September 2015, 395 patients were randomized at 17 sites in China. None withdrew their informed consent to take part in this study. As shown in , five patients in the XINSORB arm crossed over to the other arm because the scaffolds did not be delivered to target lesions. One patient in the SES arm received a non-study device. The per-treatment-evaluation (PTE) population thus comprised 389 patients in the randomization part (195 XINSORB and 194 SES). We reached 185, 193, and 191 patients in the XINSORB arm and 186, 186, and 181 patients in the SES arm at the 1-, 2-, and 3-year follow-ups. The clinical follow-up rates in the XINSORB arm at 1, 2, and 3 years were 92.5%, 96.5%, and 95.5%, respectively, and these rates were similar in the two randomized arms.

Figure 1

The flow chart of the XINSORB RCT. RCT, randomized control trial; ITT, intention-to-treat; PTE, per-treatment evaluation; SES, sirolimus-eluting stent.

Baseline information of the patients, lesions, and procedures in the ITT population is shown in . The patient demographics, risk factors, and lesion characteristics were well-balanced between the two arms. We classified most lesions treated in this study as ACC/AHA A or B1 lesions (95.7% for XINSORB and 92.8% for SES, P=0.57). More lesions were predicated in the XINSORB arm than in the SES arm (99.0% vs. 91.2%, P=0.0001). Balloons used for predilation in the XINSORB arm were larger in diameter than those in the SES arm (2.88±0.46 vs. 2.77±0.45 mm P=0.01). The rate of post-dilation in the XINSORB arm was much higher than that in the SES arm (94.8%, vs. 73.1%, P<0.001), although there was no difference regarding the size of the balloon or the pressure used for post-dilation.

Table 1

Baseline patient and lesion characteristics, ITT population

Variable	XINSORB	SES	P value
Baseline patient demographics (per patient)	N=200	N=195
Age	60.2±8.3	60.0±8.6	0.82
Male (%)	67.5 (135/200)	67.2 (131/195)	0.95
Body mass index (kg/m2)	24.6±3.2	25.1±3.3	0.30
Current smoker (%)	27.0 (54/200)	28.7 (56/195)	0.91
Hypertension (%)	60.5 (121/200)	53.8 (105/195)	0.18
Dyslipidemia (%)	14.5 (29/200)	12.3 (24/195)	0.52
Type-2 diabetes (%)	24.5 (49/200)	21.5 (42/195)	0.83
Stable angina (%)	30.0 (60/200)	27.7 (54/195)	0.92
Unstable angina (%)	39.5 (79/200)	39.5 (77/195)
Myocardial infarction (%)	14.0 (28/200)	15.4 (28/195)	0.70
Prior PCI (%)	13.5 (27/200)	8.2 (16/195)	0.09
Prior CABG (%)	0.0 (0/200)	0.0 (0/195)	NA
Left ventricular ejection fraction (%)	63.4±6.4	63.4±7.3	1.0
One target lesion treated (%)	95.0 (190/200)	89.7 (175/195)	0.07
Two target lesions treated (%)	5.0 (10/200)	9.7 (19/195)
Three lesions treated (%)	0 (0/200)	0.5 (1/195)
Baseline target lesion characteristics (per lesion)	N=210	N=216
ACC/AHA lesion type			0.57
A (%)	69.0 (145/210)	66.2 (143/216)
B1 (%)	26.7 (56/210)	26.4 (57/216)
B2 (%)	1.4 (3/210)	1.9 (4/216)
C (%)	2.9 (6/210)	5.6 (12/216)
Eccentric (%)	72.4 (152/210)	69.4 (150/216)	0.50
Number of devices implanted	222	221	0.21
Mean device implanted	1.06±0.29	1.02±0.15	0.13
Procedural information (per lesion)	N=210	N=216
Pre-dilation performed (%)	99.0 (208/210)	91.2 (197/216)	0.0001
Post-dilation performed (%)	94.8 (199/210)	73.1 (158/216)	<0.001
Balloon diameter
Pre-dilation (mm)	2.88±0.46	2.77±0.45	0.01
Post-dilation (mm)	3.26±0.38	3.22±0.40	0.35
Balloon pressure
Pre-dilation (atm)	12.06±3.12	11.86±3.31	0.52
Deployment (atm)	12.48±2.81	13.08±2.90	0.03
Post-dilation (atm)	16.89±3.42	17.47±3.45	0.12
Total device length (mm)	20.58±5.11	21.79±5.24	0.01
Device success (%)	96.8 (215/222)	100 (221/221)	0.01

ITT, intention-to-treat; SES, sirolimus-eluting stent.

There were 118 patients in the XINSORB arm (59.0%) and 103 patients in the SES arm (52.8%) who were still on dual antiplatelet therapy (DAPT) with aspirin and clopidogrel at 3-year follow-up (P=0.34).

Clinical outcomes

The 3-year endpoints of TLF (4.0% and 6.2%, P=0.29), PoCE (8.5% and 8.7%, P=0.86), MACE (4.0% and 6.2%, P=0.29), and TVF (4.5% and 6.7%, P=0.31) were comparable in the XINSORB and SES arms, respectively. Five patients died in the XINSORB arm. Two deaths were cardiac deaths; the first patient died 308 days after the index procedure because of unknown reasons, while the other died 462 days after the index procedure. This patient had received a XINSORB scaffold (3.5 mm × 18 mm) in the proximal left circumflex artery on April 27, 2015. We observed a favorable result at the one-year routine angiographic follow-up per protocol. Recurrent chest pain was recorded on July 25, 2016. Repeated angiography showed thrombosis at the treated site, and a metallic stent was deployed. However, the patient died on August 1, 2016. In the SES arm, there was only one noncardiac death. There were no significant differences between the two arms in any part endpoints for up to 3 years ( and ).

Table 2

Three-year clinical outcomes, ITT population

Variable	XINSORB	TIVOLI	P value
Number of patients	200	195
Composite endpoints (%)
DoCE (TLF)	4.0 (8/200)	6.2 (12/195)	0.29
PoCE	8.5 (17/200)	8.7 (17/195)	0.86
MACE	4.0 (8/200)	6.2 (12/195)	0.29
TVF	4.5 (9/200)	6.7 (13/195)	0.31
Individual component endpoints (%)
All-cause death	2.5 (5/200)	0.5 (1/195)	0.22
Cardiac death	1.0 (2/200)	0 (0/195)	NA
All MI	1.0 (2/200)	0 (0/195)	0.50
Q-wave MI	1.0 (2/200)	0 (0/195)	NA
Non-Q-wave MI	0 (0/200)	0 (0/195)	NA
TV-MI	1.0 (2/200)	0 (0/195)	NA
Q-wave MI	1.0 (2/200)	0 (0/195)	NA
Non-Q-wave MI	0 (0/200)	0 (0/195)	NA
All revascularization	6.5 (13/200)	8.2 (16/195)	0.46
ID revascularization	4.0 (8/200)	6.7 (13/195)	0.21
Non-ID revascularization	2.5 (5/200)	1.5 (3/195)	NA
All TVR	4.0 (8/200)	6.7 (13/200)	0.21
ID-TVR	4.0 (8/200)	6.7 (13/195)	0.21
Non-ID-TVR	0 (0/200)	0 (0/195)	NA
All TLR	3.5 (7/200)	6.2 (12/195)	0.19
ID-TLR	3.5 (7/200)	6.2 (12/195)	0.19
Non-ID-TLR	0 (0/200)	0 (0/195)	NA
Device thrombosis (%)
All (0–1,095 days)	1.0 (2/200)	0 (0/195)	0.50
Definite	1.0 (2/200)	0 (0/195)	0.50
Probable	0 (0/200)	0 (0/195)	NA
Acute (≤1 day)	0 (0/200)	0 (0/195)	NA
Subacute (1–31 days)	0 (0/200)	0 (0/195)	NA
Late (31–365 days)	0.5 (1/200)	0 (0/195)	NA
Very late (1–2 years)	0.5 (1/200)	0 (0/195)	NA
Very late (2–3 years)	0 (0/200)	0 (0/195)	NA

ITT, intention-to-treat; DoCE, device-oriented composite endpoint; PoCE, patient oriented composite endpoints; MACE, major adverse cardiac events; TVF, target vessel failure; MI, myocardial infarction; TV-MI, target vessel myocardial infarction; TVR, target vessel revascularization.

Figure 2

Kaplan-Meier curve of (A) TLF, (B) PoCE, (C) MACE, (D) ID-TLR, (E) TV-MI, and (F) all-cause death up to 3 year follow-up. TLF, target lesion failure; PoCE, patient oriented composite endpoints; MACE, major adverse cardiac events; ID-TLR, ischemia-driven target lesion revascularization; TV-MI, target vessel myocardial infarction.

Device thrombosis

The 3-year rates of device thrombosis were low and comparable between the XINSORB and SES arms (1.0% and 0%, P=0.5). Angiography confirmed both thrombosis events in the XINSORB arm. One patient suffered recurrent chest pain 92 days after scaffold deployment. Electrocardiography revealed Q-wave MI in the anterior wall. Emergent angiography was performed and showed thrombosis in the XINSORB-treated segment. We deployed another metallic stent. The other thrombosis event was recorded 455 days after the index procedure, and the patient died as previously described. Both patients were still on DAPT at the time of the thrombosis event. We recorded no thrombosis events of 2 and 3 years after the index procedure.

Discussion

The main findings of this study were: (I) the XINSORB BRS was as effective as a traditional metallic SES for up to 3 years after the treatment of human coronary de novo lesions with moderate and simple complexity, and (II) the 3-year rate of device thrombosis was low and comparable between the two devices.

Although significant achievements have been made in BRS design in the past decade, recently revealed results had increased concerns on the long-term risks of TLF and scaffold thrombosis using such devices (14-16). The 3-year outcome of the ABSORB II study showed rates of TLF and device thrombosis of 10% and 3% for the BVS, respectively, which were significantly higher than the corresponding rates for the XIENCE stent (5% and 0%). Similarly, the 3-year results of the ABSORB III study showed a significantly higher rate of device thrombosis for the BVS than the XIENCE stent (2.3% vs. 0.7%, P=0.01), although the rate of TLF was comparable between the two devices (13.4% vs. 10.4%, P=0.055). However, the 3-year results of the ABSORB China study were varied. The rates of TLF and definite/probable thrombosis in patients treated with the BVS were 5.5% and 0.9%, respectively, which were like the rates in patients treated with the XIENCE stent (4.7% and 0%) (6). The rate of both TLF and device thrombosis at the 3-year follow-up was significantly lower than the results retrieved outside of China. In our study, we found that 3-year rates of TLF and device thrombosis were low for the XINSORB scaffold and like those in the ABSORB China study. The PSP (preparing the lesion with optimal predilation, properly sizing the vessel, and optimal post-dilation with high pressure) technique was considered improving outcomes of BRS treatment. Data from the ABSORB IV study showed that treatment with the polymeric BVS using the PSP technique resulted in noninferior 30-day and 1-year TLF rates compared with treatment with the XIENCE stent (17). A reference vessel diameter less than 2.25 mm was a predictor of TLF (RR 1.72, 95% CI: 1.28–2.32, P=0.0005) and device thrombosis (RR 2.80, 95% CI: 1.37–5.71, P=0.006). In the ABSORB China study, fewer small vessels (RVD <2.25 mm) (9.6%) were treated with the BVS than in the ABSORB II (19.1%) and ABSORB III (18.3%) studies. In our study, most lesions treated with the XINSORB scaffold were predilated and post dilated, contributing to the favorable results. Long-term DAPT was associated with lower MACE and thrombosis rates (18,19). Lactic acid resulting from biodegradation of the PLLA backbone is a sustainable inducer of vessel wall inflammation, which might cause scaffold thrombosis. Ideally, DAPT should be supported until full bioabsorption of the PLLA struts (20). However, only 29.8% of patients treated with the BVS in the ABSORB II study were on DAPT at the 3-year follow-up (21). In our study, 59% of patients treated with the XINSORB scaffold were still taking aspirin and clopidogrel at 3 years, which may have resulted in a low rate of scaffold thrombosis.

There was a sharp increase in the Kaplan-Meier curves for TLF, PoCE, MACE, and ID-TLR at 12 months post-procedure. One explanation is that most patients with ischemic symptoms were angiographically examined and revascularized at the 12-month follow-up according to the protocol, although symptoms of angina were routinely recorded. We closely monitored these patients during the study. They were admitted to hospitals if severe chest pain or MI occurred. These curves remained steady from year 1 through year 3 in SES-treated patients, suggesting no added adverse events occurred. However, there was a clear but mild increase in the curves of clinical events beyond one year in the XINSORB-treated population, although the rates of TLF, PoCE, MACE, and ID-TLR is still lower than those in the SES arm. It was believed there was a so-called “late catch-up phenomenon” after first-generation drug-eluting stent (DES) implantation (22). The incidence of very late stent thrombosis and TLR was significantly higher after DES implantation than after bare-metal stent (BMS) implantation on long-term follow-up (23). Compared with patients not showing the late catch-up phenomenon, those exhibiting the late catch-up phenomenon showed slow but significant additive LLL occurring from the early to long-term follow-ups (22,24). Also, neoatherosclerosis with a different morphological appearance was observed by optical coherence tomography (OCT) in the restenotic area (25,26). We cannot conclude a “late catch-up phenomenon” in this study. The 5-year clinical results from the XINSORB first-in-human study showed relatively low rates of TLF and scaffold thrombosis (9). However, when we look at the long-term follow-up results of the serial ABSORB studies, we should know the potential risks of the very late failure of the XINSORB scaffold.

There were some limitations to this study. First, both simple and moderately complex lesions were treated in this study. The treatment of complex lesions with a BRS may be related to higher rates of scaffold thrombosis and target vessel MI (15). The XINSORB randomized clinical trial met the premarket approval requirements of the State Administration for Market Regulation in China. Patients and lesions with higher risks were excluded. Second, both the predilation of target lesions and the post-dilation of implanted scaffolds were mandatory. However, not all operators stuck to the protocol. Post dilation was performed significantly less for the metallic stent than the XINSORB scaffold, which may influence the interpretation of the study results. Third, a longer observation period must be included to verify the long-term efficacy and safety of the XINSORB scaffold. We previously reported the five-year intravascular imaging outcomes of the XINSORB scaffold in a first-in-man study (27). Although the lumen remained patent, the OCT findings showed that some struts were not fully absorbed. We must wait and see what will happen and how the vessels will heal after the struts are absorbed, and we need to confirm whether a “late catch-up phenomenon” will occur after XINSORB scaffold implantation. Finally, the sample size of this study was modest. More extensive studies with long-term follow-up data must estimate the incidence of late and very late events after XINSORB scaffold implantation. The impact of optimal implantation techniques should also be evaluated.

Conclusions

In this multicenter randomized clinical trial, the XINSORB SES showed similar efficacy and safety outcomes compared with the SES up to the 3-year follow-up. The rates of TLF and device thrombosis were low and comparable between the two arms. More extensive studies with more extended observation periods must evaluate the incidence of very late events after treatment with the XINSORB scaffold.

The article’s supplementary files as